Natera to Present New Gastrointestinal Cancer Data at the ESMO Annual Meeting
- Friday, September 18, 2020, 8:14
- Finance
- Add a comment
SAN CARLOS, Calif., Sept. 18, 2020 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new data on its personalized molecular residual disease (MRD) test, Signatera, at the 2020 European Society for Medical…
About the Author
adminasapcorp has written 41779 stories on this site.